On Wednesday, Ligand Pharmaceuticals LGND will release its latest earnings report. Here is Benzinga's outlook for the company.
Earnings and Revenue
Based on Ligand management projections, analysts predict EPS of $1.14 on revenue of $47.82 million.
In the same quarter last year, Ligand posted EPS of $1.25 on sales of $38.18 million. If the company were to report inline earnings when it publishes results Wednesday, earnings would be down 8.80 percent. Sales would be have grown 25.23 percent from the same quarter last year.
The company's reported EPS has stacked up against analyst estimates in the past like this:
| Quarter | Q3 2017 | Q2 2017 | Q1 2017 | Q4 2016 |
| EPS Estimate | 0.61 | 0.46 | 0.66 | 1.31 |
| EPS Actual | 0.69 | 0.67 | 0.57 | 1.25 |
Stock Performance
Over the last 52-week period, shares are up 49.19 percent. Given that these returns are generally positive, long-term shareholders are probably happy going into this earnings release. Analyst estimates are adjusted lower for EPS and revenues over the past 90 days.
Analysts seem to have settled on a Neutral rating with Ligand Pharmaceuticals. The strength of this rating has maintained conviction over the past three months. Most Common Rating: Neutral
Conference Call
Ligand's Q4 is scheduled to hold a conference call at 4:30 p.m. ET and it can be accessed here: https://investor.ligand.com/investor-presentations
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
